Previous 10 | Next 10 |
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.8 million pa...
Francesca's Holdings FRAN -18% on filing for bankruptcy.Chembio Diagnostics CEMI -13% after FDA rejects Chembio's EUA application for rapid antibody test panel.Lizhi (LIZI) -12%.Ollie's Bargain Outlet Holdings OLLI -11% on Q3 earnings release.Cambium Networks CMB...
HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David...
Salarius Pharmaceuticals, Inc. (SLRX) Q3 2020 Earnings Conference Call November 11, 2020 04:30 PM ET Company Participants Jason Rando - Tiberend Strategic Adviser David Arthur - Director & Chief Executive Officer Mark Rosenblum - Chief Financial Officer Daniela Santiesteban - Director, Re...
Salarius Pharmaceuticals (SLRX): Q3 GAAP EPS of -$0.10 in-line.Revenue of $1.38M (+58.6% Y/Y) beats by $0.04M.Cash and cash equivalents of $9.6M.Press Release For further details see: Salarius Pharmaceuticals EPS in-line, beats on revenue
HOUSTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for children and adults with pediatric cancers, solid tumors and other cancers, today reported its corporate and finan...
HOUSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing treatments for pediatric cancers, solid tumors and other cancers, announced that the Company will host a conference call and live audio webcast...
HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC , a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present at the BIO Investor Forum Digital conf...
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and ind...
HOUSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced its participation at two upcoming investor conferences during the month of September. ...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NASDAQ Market:
Salarius Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is one of today's top gainers. The company's shares have moved 57.21% on the day to $3.37. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Secli...
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...